Journal
OPHTHALMOLOGY AND THERAPY
Volume 10, Issue 2, Pages 337-348Publisher
SPRINGER INT PUBL AG
DOI: 10.1007/s40123-021-00345-2
Keywords
Razumab; Biosimilars; Ranibizumab; Anti-vascular endothelial growth factor; Safety profile
Categories
Ask authors/readers for more resources
The study evaluated the safety profile of intravitreal ranibizumab biosimilar molecule, Razumab, in chorioretinal disorders. The results showed that adverse reactions were similar to other anti-VEGF drugs, suggesting IVRz is a safe option for managing chorioretinal disorders in real-world settings.
Introduction To assess the safety profile of the intravitreal ranibizumab biosimilar molecule, Razumab(R) (Intas Pharmaceuticals, Ahmedabad, India) in chorioretinal disorders under real-world conditions. Methods This was a multicenter, retrospective chart review which included patients from 15 centers receiving intravitreal Razumab (IVRz) injections from 2016 to 2020. Patient demographics, ocular examination data, and detailed safety information regarding serious adverse events (SAE) or serious adverse drug reactions (sADR), and non-serious AEs (nsAE) or non-serious ADRs (nsADR) occurring within 1 month of IVRz injections were compiled. Results A total of 6404 eyes of 6404 patients received 9406 IVRz injections [mean (+/- SD) = 1.49 (+/- 0.63)] during 4.25 years. Adverse events were reported after 1978 injections (21.03%): 64.16% nsAE, 32.96% nsADR, 2.37% sADR, and 0.51% SAE. The most frequent adverse events were subconjunctival hemorrhage (8.2% of total injections), transient blurring of vision (6.5% of total injections), and mild ocular pain (5.27% of total injections). Serious ocular (31 cases with retinal pigment epithelial tears [0.33%], two cases of non-infectious vitritis [0.02%], and one case of endophthalmitis [0.01%]) and systemic (seven patients with non-fatal myocardial infarction [0.12%] and six patients with non-fatal cerebrovascular accident [0.09%]) adverse events were infrequent. Conclusion The study reports the largest pooled safety data on IVRz use in a real-world scenario. The results did not raise any new ocular or systemic safety concerns for the biosimilar agent, with the incidence and spectrum of adverse reactions similar to those reported with other anti-vascular endothelial growth factor (anti-VEGF) drugs. The real-world evidence suggests that IVRz is a safe anti-VEGF agent in the management of chorioretinal disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available